Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Binge alcohol consumption aggravates oxidative stress and promotes pathogenesis of NASH from obesity-induced simple steatosis.

Minato T, Tsutsumi M, Tsuchishima M, Hayashi N, Saito T, Matsue Y, Toshikuni N, Arisawa T, George J.

Mol Med. 2014 Dec 10;20:490-502. doi: 10.2119/molmed.2014.00048.

2.

CYP2E1 potentiates binge alcohol-induced gut leakiness, steatohepatitis, and apoptosis.

Abdelmegeed MA, Banerjee A, Jang S, Yoo SH, Yun JW, Gonzalez FJ, Keshavarzian A, Song BJ.

Free Radic Biol Med. 2013 Dec;65:1238-45. doi: 10.1016/j.freeradbiomed.2013.09.009. Epub 2013 Sep 21.

3.

Limited Excessive Voluntary Alcohol Drinking Leads to Liver Dysfunction in Mice.

Wegner SA, Pollard KA, Kharazia V, Darevsky D, Perez L, Roychowdhury S, Xu A, Ron D, Nagy LE, Hopf FW.

Alcohol Clin Exp Res. 2017 Feb;41(2):345-358. doi: 10.1111/acer.13303. Epub 2017 Jan 19.

4.

Aerobic exercise training in the treatment of non-alcoholic fatty liver disease related fibrosis.

Linden MA, Sheldon RD, Meers GM, Ortinau LC, Morris EM, Booth FW, Kanaley JA, Vieira-Potter VJ, Sowers JR, Ibdah JA, Thyfault JP, Laughlin MH, Rector RS.

J Physiol. 2016 Sep 15;594(18):5271-84. doi: 10.1113/JP272235. Epub 2016 May 27.

5.

Olmesartan ameliorates a dietary rat model of non-alcoholic steatohepatitis through its pleiotropic effects.

Kurita S, Takamura T, Ota T, Matsuzawa-Nagata N, Kita Y, Uno M, Nabemoto S, Ishikura K, Misu H, Ando H, Zen Y, Nakanuma Y, Kaneko S.

Eur J Pharmacol. 2008 Jul 7;588(2-3):316-24. doi: 10.1016/j.ejphar.2008.04.028. Epub 2008 Apr 16.

PMID:
18501344
7.

Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis.

Ota T, Takamura T, Kurita S, Matsuzawa N, Kita Y, Uno M, Akahori H, Misu H, Sakurai M, Zen Y, Nakanuma Y, Kaneko S.

Gastroenterology. 2007 Jan;132(1):282-93. Epub 2006 Oct 12.

PMID:
17241878
8.

Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis.

Yamaguchi K, Yang L, McCall S, Huang J, Yu XX, Pandey SK, Bhanot S, Monia BP, Li YX, Diehl AM.

Hepatology. 2007 Jun;45(6):1366-74.

PMID:
17476695
9.

Mitochondrial dysfunction precedes insulin resistance and hepatic steatosis and contributes to the natural history of non-alcoholic fatty liver disease in an obese rodent model.

Rector RS, Thyfault JP, Uptergrove GM, Morris EM, Naples SP, Borengasser SJ, Mikus CR, Laye MJ, Laughlin MH, Booth FW, Ibdah JA.

J Hepatol. 2010 May;52(5):727-36. doi: 10.1016/j.jhep.2009.11.030. Epub 2010 Mar 4.

10.

Reduced hepatic eNOS phosphorylation is associated with NAFLD and type 2 diabetes progression and is prevented by daily exercise in hyperphagic OLETF rats.

Sheldon RD, Laughlin MH, Rector RS.

J Appl Physiol (1985). 2014 May 1;116(9):1156-64. doi: 10.1152/japplphysiol.01275.2013. Epub 2014 Feb 27.

11.

Exercise-induced attenuation of obesity, hyperinsulinemia, and skeletal muscle lipid peroxidation in the OLETF rat.

Morris RT, Laye MJ, Lees SJ, Rector RS, Thyfault JP, Booth FW.

J Appl Physiol (1985). 2008 Mar;104(3):708-15. Epub 2007 Dec 13.

12.

Investigation into the antioxidant role of arginine in the treatment and the protection for intralipid-induced non-alcoholic steatohepatitis.

Abu-Serie MM, El-Gamal BA, El-Kersh MA, El-Saadani MA.

Lipids Health Dis. 2015 Oct 14;14:128. doi: 10.1186/s12944-015-0124-0.

13.

Salidroside alleviates oxidative stress in the liver with non- alcoholic steatohepatitis in rats.

Yang ZR, Wang HF, Zuo TC, Guan LL, Dai N.

BMC Pharmacol Toxicol. 2016 Apr 14;17:16. doi: 10.1186/s40360-016-0059-8.

14.

Induction of CYP2E1 in non-alcoholic fatty liver diseases.

Aljomah G, Baker SS, Liu W, Kozielski R, Oluwole J, Lupu B, Baker RD, Zhu L.

Exp Mol Pathol. 2015 Dec;99(3):677-81. doi: 10.1016/j.yexmp.2015.11.008. Epub 2015 Nov 10.

15.
16.

Critical role of cytochrome P450 2E1 (CYP2E1) in the development of high fat-induced non-alcoholic steatohepatitis.

Abdelmegeed MA, Banerjee A, Yoo SH, Jang S, Gonzalez FJ, Song BJ.

J Hepatol. 2012 Oct;57(4):860-6. doi: 10.1016/j.jhep.2012.05.019. Epub 2012 Jun 2.

17.

Chronic NOS inhibition accelerates NAFLD progression in an obese rat model.

Sheldon RD, Padilla J, Jenkins NT, Laughlin MH, Rector RS.

Am J Physiol Gastrointest Liver Physiol. 2015 Mar 15;308(6):G540-9. doi: 10.1152/ajpgi.00247.2014. Epub 2015 Jan 8.

18.

Alcohol steatosis and cytotoxicity: the role of cytochrome P4502E1 and autophagy.

Wu D, Wang X, Zhou R, Yang L, Cederbaum AI.

Free Radic Biol Med. 2012 Sep 15;53(6):1346-57. doi: 10.1016/j.freeradbiomed.2012.07.005. Epub 2012 Jul 20.

19.

Tranilast, an antifibrogenic agent, ameliorates a dietary rat model of nonalcoholic steatohepatitis.

Uno M, Kurita S, Misu H, Ando H, Ota T, Matsuzawa-Nagata N, Kita Y, Nabemoto S, Akahori H, Zen Y, Nakanuma Y, Kaneko S, Takamura T.

Hepatology. 2008 Jul;48(1):109-18. doi: 10.1002/hep.22338.

PMID:
18571789
20.

Model of nonalcoholic steatohepatitis.

Lieber CS, Leo MA, Mak KM, Xu Y, Cao Q, Ren C, Ponomarenko A, DeCarli LM.

Am J Clin Nutr. 2004 Mar;79(3):502-9.

PMID:
14985228

Supplemental Content

Support Center